Marksans Pharma Limited announced the outcome of its Board Meeting held on February 05, 2026, where the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025, were approved. The company's statutory auditors, M S K A & Associates LLP, submitted their Limited Review Reports with an unmodified opinion for both standalone and consolidated results. The Board Meeting commenced at 12:25 p.m. and concluded at 01:15 p.m. It was also noted that the company's statutory auditors, M S K A & Associates, have converted from a partnership firm to a limited liability partnership firm, M S K A & Associates LLP, effective January 12, 2026, with a new ICAI Firm Registration Number (FRN) of 105047W/W101187. The financial results indicate that for the quarter ended December 31, 2025, consolidated revenue from operations stood at ₹1,746.71 crore, with a profit after tax of ₹743.63 crore. For the nine months ended December 31, 2025, consolidated revenue was ₹4,078.60 crore, and profit after tax was ₹1,038.58 crore. On a standalone basis for the quarter ended December 31, 2025, revenue from operations was ₹388.57 crore, and profit after tax was ₹50.81 crore. For the nine months ended December 31, 2025, standalone revenue was ₹1,086.86 crore, with a profit after tax of ₹150.56 crore. Subsequent to the quarter, the company formed two new wholly-owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland on January 16, 2026, and Marksans (Canada) Inc. in Canada on January 22, 2026.
